Aerie Pharmaceuticals has initiated dosing in a phase 2 clinical trial of netarsudil ophthalmic solution in Japan, according to a press release.
In accordance with Japan’s Pharmaceuticals and Medical Devices Agency, the prospective, double-masked, multicenter, placebo-controlled, parallel group trial is being conducted as a precursor to phase 3 registration trials.
The IOP-reducing effect and safety of three concentrations of netarsudil (0.01%, 0.02% and 0.04%) will be evaluated over a 28-day period.
“Building upon the positive topline results of our pilot phase 2 study, we are very
Uncategorized